Consistently, our study showed that among insulin-treated patients with T2D, GLP-1 RA therapy was associated with a markedly lower risk of amputation than either DPP-4 inhibitors or sulfonylureas. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.